Methyl 6-methyl-2-propan-2-ylpyrimidine-4-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: Methyl 6-methyl-2-propan-2-ylpyrimidine-4-carboxylate
• 英文别名: methyl 6-methyl-2-propan-2-ylpyrimidine-4-carboxylate
• 化学式: C₁₀H₁₄N₂O₂
• 分子量: 194.23
• InChiKey: GKPJKICXZJSXGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE
  申请人：PETRUKHIN Konstantin

  公开号：US20160024007A1

  公开（公告）日：2016-01-28

  The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatment of diseases characterized by excessive lipofuscin accumulation in the retina.

  本发明提供了八氢环戊吡咯化合物，其结构如下：（结构式表示），其中psi不存在或存在，当存在时为键；R1、R2、R3、R4和R5各自独立地为H、卤素、CF或C1-C4烷基；R6不存在或存在，当存在时为H、OH或卤素；A不存在或存在，当存在时为C（O）或C（O）NH；B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或（C1-C4烷基）-CO2H，其中当B为CO2H时，A存在且为C（O）；当psi存在时，R6不存在，当psi不存在时，R6存在，或其药学上可接受的盐，用于治疗以视网膜过多脂褐质沉积为特征的疾病。
• OCTAHYDROPYRROLOPYRROLES THEIR PREPARATION AND USE
  申请人：PETRUKHIN Konstantin

  公开号：US20160046632A1

  公开（公告）日：2016-02-18

  The present invention provides compounds comprising variously substituted octahydropyrrolopyrroles, their synthesis, methods of making, methods of using, compositions and formulations thereof.

  本发明提供了包含各种取代的八氢吡咯吡咯化合物，它们的合成方法，制备方法，使用方法，以及它们的组成和配方。
• N-ALKYL-2-PHENOXYETHANAMINES, THEIR PREPARATION AND USE
  申请人：PETRUKHIN Konstantin

  公开号：US20160046649A1

  公开（公告）日：2016-02-18

  The present invention provides a compound having the structure: (structurally represented) wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R6 is alkyl; A is absent or present, and when present is —C(O)— or —C(O)NH—; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is —C(O)—, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种具有以下结构的化合物：（结构表示）其中R1、R2、R3、R4和R5各自独立地为H、卤素、CF3或C1-C4烷基；R6为烷基；A不存在或存在，当存在时为—C（O）—或—C（O）NH—；B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或（C1-C4烷基）-CO2H，其中当B为CO2H时，A存在且为—C（O）—，或其药学上可接受的盐。
• 4-phenylpiperidines, their preparation and use
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US10273243B2

  公开（公告）日：2019-04-30

  The present invention provides a compound having the structure: (structurally represented) wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R6 is H, OH, or halogen; B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterobicycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种具有以下结构的化合物：(结构表示），其中 R1、R2、R3、R4 和 R5 各自独立地为 H、卤素、CF3 或 C1-C4 烷基；R6 为 H、OH 或卤素；B 为取代或未取代的杂环、哒嗪、吡唑、吡嗪、噻二唑或三唑，其中杂环为氯取代的吲哚以外的杂环；吡唑取代时为三氟甲基以外的取代基，或其药学上可接受的盐。
• Octahydrocyclopentapyrroles, their preparation and use
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US10421720B2

  公开（公告）日：2019-09-24

  The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatment of diseases characterized by excessive lipofuscin accumulation in the retina.

  本发明提供具有以下结构的八氢环戊吡咯化合物：(结构表示）其中psi不存在或存在，存在时为键；R1、R2、R3、R4和R5各自独立地为H、卤素、CF或C1-C4烷基；R6不存在或存在，存在时为H、OH或卤素；A不存在或存在，存在时为C(O)或C(O)NH；B 是取代或未取代的单环、单车、杂单环、杂单车、苄基、CO2H 或 (C1-C4 烷基)-CO2H，其中当 B 是 CO2H 时，则 A 存在且为 C(O)；当 psi 存在时，则 R6 不存在，当 psi 不存在时，则 R6 存在，或其药学上可接受的盐，用于治疗以视网膜中脂褐素过度积累为特征的疾病。